Improvement of Patient-Reported Fatigue in IMerge Phase 3 Trial of Imetelstat Versus Placebo in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible to Erythropoiesis-Stimulating Agents

Mikhael A. Sekeres,1† Valeria Santini,2† Maria E. Gaidzik3† Ramzi S. Komrokji,1† Michael R. Stockman,1† Yvonne F. Madanit,1† David Valmori-Fernandez,1† Thomas Illmer,1† Anu Jorándi,1 Petra Bölöni-Gilovics,4† Antoine Reugnet,5† Kristin Creed,6± Nelson Sergeant,6± Libo Sun,7± Sheyla Maradavui,8± Amer M. Zaidi,9± and Use Platelbroek10,11±

†Department of Medicine, Division of Hematology and Medical Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio; 2Department of Medicine, Division of Hematology, University of Maryland School of Medicine, Baltimore, Maryland; 3Department of Medicine, Division of Hematology-Oncology, University of Illinois at Chicago, Chicago, Illinois; 4Department of Medicine, Division of Hematology-Oncology, University of Colorado School of Medicine, Aurora, Colorado; 5Department of Medicine, Division of Hematology-Oncology, University of Miami, Miami, Florida; 6Division of Hematology-Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 7Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; 8Division of Hematology, Department of Medicine, Mount Sinai Medical Center, New York, New York; 9Division of Hematology-Oncology, Department of Medicine, Mayo Clinic, Rochester, Minnesota; 10Leukemia and Lymphoma Society, New York, New York; 11Geron Corporation, Parsippany, New Jersey.

1Presented at the AMCP Nexus Annual Meeting, October 16-19, 2023; Orlando, FL, USA.

Introduction

Aim

Methods

Results

Fig. 1. Score Improvement in FACIT-Fatigue Scale Score

Supplemental Table 7: Other RBC-TI and Response Relationships

Table 2. PRO Population Demographics

Fig. 5. Kaplan-Meier Estimate of Time to First Sustained Meaningful Improvement in Fatigue

Fig. 4. Associations of Improvement in Fatigue and Clinical Responses

Fig. 3. Kaplan-Meier Estimate of Time to First Sustained Meaningful Improvement in FACIT-Fatigue Scale Score

Table 1. PRO Population Demographics

Fig. 2. Kaplan-Meier Estimate of Time to First Sustained Meaningful Improvement in FACIT-Fatigue Scale Score

Conclusions

Fig. 6. Graphs of Modified Bone Marrow Changes Based on FACIT-Fatigue Scale Scores by WHO

Fig. 1. Kaplan-Meier Estimate of Time to First Sustained Meaningful Improvement in FACIT-Fatigue Scale Score

Fig. 1. Kaplan-Meier Estimate of Time to First Sustained Meaningful Improvement in FACIT-Fatigue Scale Score

Supplemental Table 7: Other RBC-TI and Response Relationships

Table 2. PRO Population Demographics

Fig. 2. Kaplan-Meier Estimate of Time to First Sustained Meaningful Improvement in FACIT-Fatigue Scale Score

Fig. 3. Kaplan-Meier Estimate of Time to First Sustained Meaningful Improvement in FACIT-Fatigue Scale Score

Table 1. PRO Population Demographics

Fig. 5. Kaplan-Meier Estimate of Time to First Sustained Meaningful Improvement in Fatigue

Supplemental Table 7: Other RBC-TI and Response Relationships

Table 2. PRO Population Demographics

Fig. 1. Kaplan-Meier Estimate of Time to First Sustained Meaningful Improvement in FACIT-Fatigue Scale Score

Fig. 2. Kaplan-Meier Estimate of Time to First Sustained Meaningful Improvement in FACIT-Fatigue Scale Score

Supplemental Table 7: Other RBC-TI and Response Relationships

Table 2. PRO Population Demographics

Fig. 5. Kaplan-Meier Estimate of Time to First Sustained Meaningful Improvement in Fatigue

Supplemental Table 7: Other RBC-TI and Response Relationships

Table 2. PRO Population Demographics

Fig. 1. Kaplan-Meier Estimate of Time to First Sustained Meaningful Improvement in FACIT-Fatigue Scale Score

Fig. 2. Kaplan-Meier Estimate of Time to First Sustained Meaningful Improvement in FACIT-Fatigue Scale Score

Supplemental Table 7: Other RBC-TI and Response Relationships

Table 2. PRO Population Demographics

Fig. 5. Kaplan-Meier Estimate of Time to First Sustained Meaningful Improvement in Fatigue

Supplemental Table 7: Other RBC-TI and Response Relationships

Table 2. PRO Population Demographics

Fig. 1. Kaplan-Meier Estimate of Time to First Sustained Meaningful Improvement in FACIT-Fatigue Scale Score

Fig. 2. Kaplan-Meier Estimate of Time to First Sustained Meaningful Improvement in FACIT-Fatigue Scale Score

Supplemental Table 7: Other RBC-TI and Response Relationships

Table 2. PRO Population Demographics

Fig. 5. Kaplan-Meier Estimate of Time to First Sustained Meaningful Improvement in Fatigue

Supplemental Table 7: Other RBC-TI and Response Relationships

Table 2. PRO Population Demographics